

**Table 1:** Baseline characteristics of study participants (n =2,125 patients with chronic hepatitis B) derived from the HEPNET-Greece.

	<b>n (%)</b>
<b>Gender</b>	
<i>Male</i>	1273 (59.9)
<i>Female</i>	850 (40.0)
<i>Transsexual</i>	2 (0.1)
<b>Calendar year</b>	
2000-2003	461 (21.7)
2004-2008	1002 (47.2)
2009+	662 (31.2)
<b>Cirrhosis</b>	
<i>No</i>	2029 (95.5)
<i>Yes</i>	96 (4.5)
<i>Mean of diagnosis</i>	
<i>Biopsy</i>	35 (36.5)*
<i>Ultrasound</i>	59 (61.5)
<i>Unspecified</i>	2 (2.1)
<b>ALT</b>	
≤40 IU/L	1177 (55.4)
>40 IU/L	948 (44.6)
<b>AST</b>	
≤40 IU/L	1448 (68.1)
>40 IU/L	677 (31.9)
<b>HBV DNA</b>	
≤2000 IU/ml	1030 (48.5)
>2000 IU/ml	1095 (51.5)
<b>HBeAg</b>	
<i>Negative</i>	1885 (88.7)
<i>Positive</i>	126 (5.9)
<i>Unknown</i>	114 (5.4)
	<b>Median (IQR)</b>
<b>Age, years</b>	44.8 (33.0, 56.7)
<b>Estimated Infection time, years</b>	1.7 (0.2, 9.8)

n: number, ALT: alanine transaminase, AST: aspartate transaminase, HBV: hepatitis B virus, HBeAg: hepatitis B e antigen, IQR: inter-quartile range \*: percentages calculated among cirrhotics.